Clinical Trial Update: Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating stereotactic body radiotherapy in combination with sorafenib for metastatic, recurrent, or unresectable renal cell carcinoma; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (sorafenib) (sorafenib)

Snippet

Sponsor: Duke University | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2010-12-15